Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Shan Hawramee

Physician Assistant North Tonawanda, NY Physician Assistant

NPI 1356824007 CMS profile 10772852

43 Niagara St, North Tonawanda, NY 14120

Open in the dashboard

General payments

$6,936

378 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Shan Hawramee of North Tonawanda, NY is reported in the CMS Open Payments database as having received $6,936 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,756 85
2022 General $2,388 133
2021 General $2,792 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shan Hawramee
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shan Hawramee were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shan Hawramee Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,792 $132 $37–$438 $132
2022 $2,388 $155 $48–$522 $149
2023 $1,756 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,163 63 payments
  2. Lilly USA, LLC $829 40 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $666 46 payments
  4. AstraZeneca Pharmaceuticals LP $562 28 payments
  5. Novo Nordisk Inc $509 38 payments
  6. GlaxoSmithKline, LLC. $492 30 payments
  7. Astellas Pharma US Inc $385 17 payments
  8. AbbVie, Inc. $377 20 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $324 13 payments
  10. Amgen Inc. $324 18 payments
  11. Other $1,306 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $6,837 377 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2023
  1. XIFAXAN $666 46 payments
  2. JARDIANCE Diabetes $656 33 payments
  3. JARDIANCE Diabetes $478 25 payments
  4. TRELEGY ELLIPTA $429 26 payments
  5. RYBELSUS $422 33 payments
  6. STIOLTO RESPIMAT $419 25 payments
  7. FARXIGA $410 17 payments
  8. Ozempic $361 30 payments
  9. Kerendia $324 13 payments
  10. Repatha $291 16 payments
  11. Other $4,019 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

318

Median for Physician Assistant: 241

Drug cost

$2,523

Median for Physician Assistant: $4,110

Branded share of claims

32.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 31 $557
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 30 $376
Fluticasone Propionate Generic 21 $220
Azithromycin Generic 50 $208
Rosuvastatin Calcium Generic 16 $187
Mupirocin Generic 19 $149
Ciprofloxacin Hcl Generic 13 $143
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 17 $137
Valacyclovir Valacyclovir Hcl Brand 11 $135
Cephalexin Generic 20 $132

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$42,670

Of which drugs: $1,149

Medicare patients

421

Average age 76

Services billed

844

295 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 56%
Osteoporosis 31%
Ischemic heart disease 26%
Cancer 22%
Depression 21%
Diabetes 18%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 12 12 $962

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record